|
US Pharmaceutical Market Outlook 2011-2021
|
|||||||||||
| Preis** (Lieferformat): |
Versandkostenfrei ** WICHTIG: Alle Preise sind netto ausgewiesen. Abhängig von Versand- und Leistungsort ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Der korrekte Gesamtendpreis wird Ihnen mit der Angabe Ihrer Rechnungsadresse, USt-ID-Nr. etc. im Bestellverlauf ausgewiesen. Weitere Informationen zu den Bestandteilen des Kaufpreises finden Sie in unseren FAQs. |
|||||||||||
| Zahlen und Fakten zur Studie: |
Our report gives you the following advantages: How will the US pharma market develop, and which companies and products will be best placed to benefit from legal, regulatory and economic changes? This report gives you the trends and answers you need. You can have our report today Nobody with an interest in the US pharma market should overlook our new study. We conclude that the US healthcare reforms will have important effects on the pharma industry. Do you want to understand future trends and harness the opportunities? Order our report now, making sure you don't miss out. Please let us help today. 170 seiten | |||||||||||
| Inhalt der Studie: |
Do you want to know the effects of the Obama government's legislation for US healthcare? Insurance coverage will be extended, expanding the pharma market. But at what price to the pharmaceutical indus.....
Do you want to know the effects of the Obama government's legislation for US healthcare? Insurance coverage will be extended, expanding the pharma market. But at what price to the pharmaceutical industry in rebates and other costs? Will the healthcare reforms underwrite another decade of growth in the US pharma market, or has it reached its limits? US Pharmaceutical Market Outlook 2011-2021 answers those questions with a deep, wide-ranging survey of the market. Our report analyses the leading therapeutic categories in the US market. We assess which areas have the strongest potential for growth and the most-promising R&D pipelines. You will also find out which areas are most threatened with contraction as patent expiries occur. Order today, staying ahead. We provide forecasts and discussions for the top drugs in the US market. We profile the US market's leading players, with analyses of their growth strategies. Our report covers their plans to expand and diversify their portfolios, restructure their operations and consolidate positions in emerging markets. We provide revenue forecasts for the top companies in the US market and worldwide, putting the US market in context. Our new report also provides analyses of the US generic drug market and the US OTC pharma market, studying the market drivers and restraints. We provide forecasts for those markets, and for leading companies in those rising sectors. This report contains interviews with experts on prospects for the US market this decade, discussing matters such as: • FDA funding and regulatory transparency • The biosimilars market in light of the 2010 healthcare reforms • The erosion of industry leadership to Europe • The pressure on pricing within the US health insurance industry • The legal and political complexities of the US pharma market this decade. Analysis and expert opinion to aid your work - so you won't be left behind US Pharmaceutical Market Outlook 2011-2021 critically examines the world's most important pharma market. You will find sales forecasts, market share analyses, discussions of products and analyses of commercial drivers and restraints. We include 120 tables and figures and two expert interviews (shown in the accompanying lists). You can stay ahead by ordering our report today, benefiting your analyses and commercial ideas. Report Highlights Companies Listed Abbott Abraxis Accord Healthcare Adimab Alcon Almirall American Consumer Products Amerisource Bergen Amgen Andrx Antisoma Apotex Arakis Ariad Arrow Asian Cancer Research Group Astellas AstraZeneca Bayer Beijing University BioCon Bioniche Pharma Biovail Laboratories Bristol-Myers Squibb Cardinal Health Cardiome Celera Celgene Celldex Center for Drug Evaluation and Research (CDER) Centocor Ortho Biotech Chiron Chugai Cleveland Clinic Cobalt Coley Pharmaceuticals Corthera Inc Cougar Biotechnology CovX Crucell Biotechnology Cumencor CVS Pharmacy Data and Safety Monitoring Board Depomed Dey Pharma Diabact Dollar Central Dr. Reddy's Laboratories Eli Lilly Emisphere Encysive Pharmaceuticals Eon Labs Facet Biotech Food and Drug Administration (FDA) Forest Fujisawa Gedeon Richter Genentech Genpharm Gilead Sciences GlaxoSmithKline Gloucester Pharmaceuticals Grifols Guangdong Province People's Hospital Handa Pharmaceuticals Health Mart Hexal AG Hospira HPS Group LLC Independent Payment Advisory Board Incyte Ipsen Itero Ivax Janssen Pharmaceutica Johnson & Johnson Kern Pharma King Kowa Leiner Health Products Laboratorios Alter Laboratorios Belac Laboratorios Cinfa Lonza Malinckdrodt Matrix Laboratories McKesson Mayo MedImmune Medivation Menarini Merck & Co Merck KGaA Merck Banyu MicuRx Millipore Mitsubishi Tanabe Mylan Mylan Dura GmbH National Children's Medical Center (Japan) Nektar Therapeutics Neolab NeuTec Nordic Bioscience Novartis NutraMax Products Novo Nordisk The Office of Surveillance and Epidemiology (OSE) Organization for Economic Co-operation and Development (OECD) Orexo Orion Laboratories OSI Otsuka Paratek Par Pharma Peking Union Medical College Hospital Perrigo Company Pharmaceutical Research and Manufacturers of America (PhRMA) Pharmascience Pfizer Pfizer Greenstone Pierre Fabre PlaNrt Finance Plexxikon PowderMed Procter and Gamble Protalix Protez Purdue Ratiopharm Reckett Benckiser Roche Sagmel Scisive Consulting Sandoz Sanofi-Aventis Schering-Plough Schwarz Seattle Genetics SeBo Serenex Shanghai Kiao Tong University Sosei Speedel Taito Talecris Targacept Targegen Target Teva Toho University Topsun Science and Technology Co University Hospital Beijing Upjohn US Centers for Disease Control & Prevention (CDC) US Congress US Department of Health and Human Services US National Institutes of Health (NIH) Vectura Vertex Pharmaceuticals Viiv Healthcare Viriom Walgreens Wal-Mart Watson World Health Organization (WHO) Wuhan National Bioindustry Base Construction WuXi Pharmatech Wyeth Xoma Yoshitomi Zhangjiang Hi-Tech Park Zhejiang Tianyuan [Studien Infos ausblenden] |
|||||||||||
|
1. Executive Summary 1.1 US Pharmaceutical Market Summary 1.2 Contents Overview 1.3 Methods of Analysis 2. The US Pharma Market in 2010 2.1 The 2010 Healthcare Reforms 2.1.1 Existing Healthcare Coverage 2.1.1.1 Medicare 2.1.1.2 Medicaid 2.1.1.3 Other Public Programmes 2.1.1.4 Employer Funded Healthcare 2.1.1.5 Private Healthcare Insurance 2.1.2 The Cost of US Healthcare 2.1.3 The Provisions of the 2010 Healthcare Reforms 2.1.4 Opposition to Reforms 2.1.5 Benefits and Costs to the Pharmaceutical Industry of the 2010 Health Care Reforms 2.2 Other Influences on the US Market in 2010 2.2.1 Pricing Policy 2.2.2 The End of the Blockbuster Model? 2.2.3 The Regulatory Environment 2.2.3.1 FDA Stringency 2.2.3.2 Lack of Transparency 2.2.3.3 Overstretch 3. Overview of US Market, 2011-2021 3.1 US Market Revenues Can Rise Significantly 3.1.1 The US and China 3.2 CNS Products Are The Largest Market Sector in 2010 3.2.1 Forecast for CNS Products 3.3 Cardiovascular Products 3.3.1 Forecast for Cardiovascular Products 3.3 Oncology Products 3.3.1 Forecast for Oncology Products 3.4 Anti-infective Products 3.4.1 Forecast for Anti-infective Products 3.5 Alimentary/Metabolism Products 3.5.1 Forecast for Metabolism Products 3.6 Other Products 4. Top Products in the US Market 4.1 Lipitor (Pfizer) 4.2 Plavix (Bristol-Myers Squibb) 4.3 Seretide (GlaxoSmithKline) 4.4 Seroquel (AstraZeneca) 4.5 Remicade (Johnson & Johnson) 5. Top Companies in the US Market 5.1 Pfizer 5.1.1 Pfizer's Growth Strategy 5.1.1.1 New Markets 5.1.1.2 Portfolio Management 5.1.1.3 Diversification and Restructuring 5.1.2 Forecast for Pfizer 5.2 Roche 5.2.1 Roche's Growth Strategy 5.2.1.1 New Markets 5.2.1.2 Portfolio Management 5.2.1.3 Diversification and Restructuring 5.2.2 Forecast for Roche 5.3 AstraZeneca 5.3.1 AstraZeneca's Growth Strategy 5.3.1.1 New Markets 5.3.1.2 Portfolio Management 5.3.1.3 Diversification and Restructuring 5.3.2 Forecast for AstraZeneca 5.4 Merck & Co. 5.4.1 Merck & Co's Growth Strategy 5.4.1.1 New Markets 5.4.1.2 Portfolio Management 5.4.1.3 Diversification and Restructuring 5.4.2 Forecast for Merck & Co. 5.5 Novartis 5.5.1 Novartis' Growth Strategy 5.5.1.1 New Markets 5.5.1.2 Portfolio Management 5.5.1.3 Diversification and Restructuring 5.5.2 Forecast for Novartis 6. US Generics Market 2011-2021 6.1 The US Generics Market Achieved 2009 Revenues of $35.6bn 6.2 Forecast for the US Generics Market, 2010-2021 6.2.1 US and China: Generics 6.3 Analysis of the US Generics Market 6.3.1 Pro-Generic Government Policies 6.3.2 Many More Blockbuster Products Will Become Susceptible to Generic Competition 6.3.3 Pricing Pressure and Regulation 6.3.4 The ANDA Backlog 6.4 Key Players in the US Generics Market 6.4.1Teva 6.4.2 Mylan 6.4.3 Sandoz 6.4.4 Hospira 6.4.5 Watson 6.5 Biosimilars 7. US OTC Market 2011-2021 7.1 The US OTC Market Achieved 2009 Revenues of $19.4bn 7.2 Forecast for the US OTC Market 7.3 Analysis of the US OTC Market 7.3.1 OTC Products Have Several Advantages 7.3.2 Rx-to-OTC Switching: The OTC Product Pipeline 7.3.3 Difficulties with OTC Switching 7.3.4 Sales Channels 7.4 Leading Companies in the US OTC Market 7.4.1 Johnson & Johnson 7.4.2 Procter & Gamble 7.4.3 Bayer 7.4.4 Novartis 7.4.5 Perrigo Company 8. Expert Opinions 8.1 Interview with Robert J. Easton 8.1.1 Pros and Cons of the 2010 Health Care Reform Bills 8.1.2 The Reform of Pricing 8.1.3 Different Strategies in the Industry 8.1.4 On Emerging Markets and the Loss of American Industry Leadership 8.2 Interview with Steven A. Grossman 8.2.1 On The Prospects for Health Care Reform 8.2.2 Opposition to the Reforms 8.2.3 Effects of the Bill 8.2.4 On Biosimilars Prospects 8.2.5 On FDA Regulation 8.2.6 On the Legal Challenge to the Industry 8.2.7 On FDA Funding 9. SWOT Analysis of US Market: Conclusions 9.1 Strengths of the US Market 9.1.1 The US Pharma Market is the Largest in the World 9.1.2 The 2010 Health Care Reforms Will Increase Coverage 9.1.3 Unmet Market Needs 9.2 Weaknesses of the US Market 9.2.1 The US Market Has Low Growth Rates 9.2.2 Margins Can Only Get Smaller 9.2.3 US Leadership and Centrality Have Decreased 9.3 Opportunities in the US Market 9.3.1 Biologicals and Biosimilars Will Grow 9.3.2 Good Prospects in Oncology 9.3.3 Opportunities in Generics and OTC Markets 9.4 Threats to the US Market 9.4.1 Opposition to Reforms 9.4.2 FDA Shortcomings 9.4.3 The Competitive Threat of China 9.5 Conclusions [Inhaltsverzeichnis ausblenden] |
||||||||||||
|
Table 2.1, Global Pharmaceutical Market by Region, Revenues ($bn), Share of Global Market (%), 2009 Table 2.2, Top 10 Global Pharmaceutical Markets, Revenues ($bn), Share of Global Market (%), 2009 Table 2.3, Types of Employer-Funded Healthcare Provision, 2010 Table 2.4, US Government Healthcare Expenditure ($bn), 2007 Table 2.5, Provisions of the 2010 Healthcare Reforms Table 2.6, Key Benefits and Costs to the Pharmaceutical Industry of the 2010 Health Care Reforms Table 3.1, US Pharma Market, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021 Table 3.2, US Pharma Market and China Pharma Market, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021 Table 3.3, Sectors in the US Market, Total Revenues ($bn), Annual Growth Rate (%), Share of Market (%), 2009 Table 3.4, Top Ten Products in the CNS Sector, US Revenues ($bn), 2009 Table 3.5, CNS Sector, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021 Table 3.6, Top Ten Products in the Cardiovascular Sector, US Revenues ($bn), 2009 Table 3.7, Cardiovascular Sector, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021 Table 3.8, Top Ten Products in the Oncology Sector, US Revenues ($bn), 2009 Table 3.9, Oncology Sector, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021 Table 3.10, Top Ten Products in the Anti-infectives Sector, US Revenues ($bn), Market Share (%), 2009 Table 3.11, Anti-infectives Sector, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021 Table 3.12, Top Ten Products in the Alimentary/Metabolic Sector, US Revenues ($bn), Market Share (%), 2009 Table 3.13, Alimentary/Metabolic Sector, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021 Table 3.14, Other Sectors, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021 Table 4.1, Top 10 Products in the US Market, US Revenues ($bn), 2009 Table 4.2, Lipitor US Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021 Table 4.3, Plavix US Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021 Table 4.4, Seretide US Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021 Table 4.5, Seroquel US Revenues ($bn), US Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021 Table 4.6, Remicade US Revenues ($bn), US Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021 Table 5.1, Top Companies in the US Market, US Revenues ($bn), Total Revenues, Market Share (%), 2009 Table 5.2, Pfizer Products Approaching Patent Expiry, 2010 Table 5.3, Pfizer Pipeline, Phase III and Later, 2010 Table 5.4, Pfizer US Revenues ($bn), Global Revenues ($bn), Annual Growth (%), CAGR (%), Share of US Market (%), 2009-2021 Table 5.5, Roche Products Approaching Patent Expiry, 2010 Table 5.6, Roche Pipeline, Phase III and Later, 2010 Table 5.7, Roche US Revenues ($bn), Global Revenues ($bn), Annual Growth (%), CAGR (%), Share of US Market (%), 2009-2021 Table 5.8, AstraZeneca Products Approaching Patent Expiry, 2010 Table 5.9, AstraZeneca Pipeline, Phase III and Later, 2010 Table 5.10, AstraZeneca US Revenues ($bn), Global Revenues ($bn), Annual Growth (%), CAGR (%), Share of US Market (%), 2009-2021 Table 5.11, Merck & Co Products Approaching Patent Expiry, 2010 Table 5.12, Merck & Co Pipeline, Phase III and Later, 2010 Table 5.13, Merck & Co US Revenues ($bn), Global Revenues ($bn), Annual Growth (%), CAGR (%), Share of US Market (%), 2009-2021 Table 5.14, Novartis Products Approaching Patent Expiry, 2010 Table 5.15, Novartis Pipeline, Phase III and Later, 2010 Table 5.16, Novartis US Revenues ($bn), Global Revenues ($bn), Annual Growth (%), CAGR (%), Share of US Market (%), 2009-2021 Table 6.1, Top National Generics Markets, Revenues ($bn), Share of Global Market (%), 2009 Table 6.2, US Generic Revenues ($bn), Annual Growth (%), CAGR (%), Share of US Market (%), 2009-2021 Table 6.3, US and China Generic Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021 Table 6.4, Top Companies in the US Generics Market, 2009, Revenues ($bn), Market Share (%), 2009 Table 6.5, Teva US Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021 Table 6.6, Mylan US Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021 Table 6.7, Sandoz US Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021 Table 6.8, Hospira US Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021 Table 6.9, Watson US Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021 Table 6.10, Some Companies in the Biosimilars Market, 2010 Table 7.1, OTC Markets Worldwide, Revenues ($bn), Global Market Share (%), 2009 Table 7.2, US OTC Market, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021 Table 7.3, US and China OTC Markets, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021 Table 7.4, Top Companies in the US OTC Market, Revenues ($bn), Market Share (%), 2009 Table 7.5, Johnson & Johnson OTC Revenues ($bn), Market Share (%), CAGR (%), 2009-2021 Table 7.6, Procter & Gamble OTC Revenues ($bn), Market Share (%), CAGR (%), 2009-2021 Table 7.7, Bayer OTC Revenues ($bn), Market Share (%), CAGR (%), 2009-2021 Table 7.8, Novartis OTC Revenues ($bn), Market Share (%), CAGR (%), 2009-2021 Table 7.9, Perrigo Company OTC Revenues ($bn), Market Share (%), CAGR (%), 2009-2021 Figure 2.1, Global Pharmaceutical Market by Region, Revenues ($bn), 2009 Figure 2.2, Top 10 National Pharmaceutical Markets, Revenues ($bn), 2009 Figure 2.3, US Government Health Care Expenditure ($bn), 2007 Figure 3.1, US Pharma Market, Revenues ($bn), 2009-2021 Figure 3.2, US and Chinese Pharma Markets, Revenues ($bn), 2009-2021 Figure 3.3, Sectors in the US Market, Total Revenues ($bn), 2009 Figure 3.4, Top Ten Products in the CNS Sector, US Revenues ($bn), 2009 Figure 3.5, CNS Sector, US Revenues ($bn), 2009-2021 Figure 3.6, Top Ten Products in the Cardiovascular Sector, US Revenues ($bn), 2009 Figure 3.7, Cardiovascular Sector, US Revenues ($bn), 2009-2021 Figure 3.8, Top Ten Products in the Oncology Sector, US Revenues ($bn), 2009 Figure 3.9, Oncology Sector, US Revenues ($bn), 2009-2021 Figure 3.10, Top Ten Products in the Anti-infectives Sector, US Revenues ($bn), Market Share (%), 2009 Figure 3.11, Anti-infectives Sector, US Revenues ($bn), 2009-2021 Figure 3.12, Top Ten Products in the Alimentary/Metabolic Sector, 2009 Figure 3.13, Alimentary/Metabolic Sector, Revenues ($bn), 2009-2021 Figure 4.1, Top Ten Products in the US Market, Revenues ($bn), 2009 Figure 4.2, Lipitor US Revenues ($bn), Non-US Revenues ($bn), 2009 Figure 4.3, Lipitor US Revenues ($bn), 2009-2021 Figure 4.4, Plavix US Revenues ($bn), Non-US Revenues ($bn), 2009 Figure 4.5, Plavix US Revenues ($bn), 2009-2021 Figure 4.6, Seretide US Revenues ($bn), Non-US Revenues ($bn), 2009 Figure 4.7, Seretide US Revenues ($bn), 2009-2021 Figure 4.8, Seroquel US Revenues ($bn), Non-US Revenues ($bn), 2009 Figure 4.9, Seroquel US Revenues ($bn), 2009-2021 Figure 4.10, Remicade US Revenues ($bn), Non-US Revenues ($bn), 2009 Figure 4.11, Remicade US Revenues ($bn), 2009-2021 Figure 5.1, Top Ten Companies in the US Market, Revenues ($bn), 2009 Figure 5.2, Pfizer US Revenues ($bn), Non-US Revenues ($bn), 2009 Figure 5.3, Pfizer US Revenues ($bn), Global Revenues ($bn), 2009-2021 Figure 5.4, Roche US Revenues ($bn), Non-US Revenues ($bn), 2009 Figure 5.5, Roche US Revenues ($bn), Global Revenues ($bn), 2009-2021 Figure 5.6, AstraZeneca US Revenues ($bn), Non-US Revenues ($bn), 2009 Figure 5.7, AstraZeneca US Revenues ($bn), Global Revenues ($bn), 2009-2021 Figure 5.8, Merck & Co US Revenues ($bn), Non-US Revenues ($bn), 2009 Figure 5.9, Merck & Co US Revenues ($bn), Global Revenues ($bn), 2009-2021 Figure 5.10, Merck & Co US Revenues ($bn), Non-US Revenues ($bn), 2009 Figure 5.11, Novartis US Revenues ($bn), Global Revenues ($bn), 2009-2021 Figure 6.1, US Generic Sales and Branded Product Sales ($bn), Share of Overall Market Revenues (%), 2009 Figure 6.2, US Generic and Branded Products Share of Overall Market Volume (%), 2009 Figure 6.3, US Generic and Branded Products Share of Overall Market Volume (%), 2009 Figure 6.4, US Generic Market Revenues ($bn), 2009-2021 Figure 6.5, US and China Generic Market Revenues ($bn), 2009-2021 Figure 6.6, Top Companies in the US Generics Market, 2009, Revenues ($bn), 2009 Figure 6.7, Teva US Revenues ($bn), 2009-2021 Figure 6.8, Mylan US Revenues ($bn), 2009-2021 Figure 6.9, Sandoz US Revenues ($bn), 2009-2021 Figure 6.10, Hospira US Revenues ($bn), 2009-2021 Figure 6.11, Watson US Revenues ($bn), 2009-2021 Figure 7.1, US OTC and Rx Revenues ($bn), 2009 Figure 7.2, OTC Markets Worldwide, Revenues ($bn), 2009 Figure 7.3, US OTC Market, Revenues ($bn), 2009-2021 Figure 7.4, US and China OTC Markets, Revenues ($bn), 2009-2021 Figure 7.5, Top Companies in the US OTC Market, Revenues ($bn), 2009 Figure 7.6, Johnson & Johnson OTC Revenues ($bn), 2009-2021 Figure 7.7, Procter & Gamble OTC Revenues ($bn), 2009-2021 Figure 7.8, Bayer OTC Revenues ($bn), 2009-2021 Figure 7.9, Novartis OTC Revenues ($bn), 2009-2021 Figure 7.10, Perrigo Company OTC Revenues ($bn), 2009-2021 [Tabellenverzeichnis ausblenden] |
||||||||||||
| Hinweis: | * Der Rechnungsbetrag für diese Studie wird in $ (Dollar) ausgewiesen. Kunden aus dem Inland bekommen von uns eine Rechnung in Euro, umgerechnet zum letztwöchigen Schlusskurs | |||||||||||
|
|
||||||||||||
